BiomX (PHGE)’s “buy” rating is reaffirmed at HC Wainwright

HC Wainwright reiterated his buy rating on shares of BiomX (NYSEMKT:PHGE – Free Report) in a research note issued to investors on Monday, Benzinga reports. They currently have a price target of €2.00 for the stock.

BiomX is trading 1.8% higher

NYSEMKT PHGE opened at $0.30 on Monday. The company’s fifty day simple moving average is $0.32 and its two hundred day simple moving average is $0.31. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.51. The stock has a market cap of $16.30 million, a price-to-earnings ratio of -0.56 and a beta of 1.36.

About BiomX

(Get a free report)

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of the skin, as well as chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis and colorectal cancer (CRC).

Featured Stories

Receive daily news and reviews for BiomX – Enter your email address below to receive a daily digest of the latest news and analyst ratings for BiomX and related companies with MarketBeat.com’s FREE daily email newsletter.